Sanofi
SAN.PAHealthcareEURONEXTDrug Manufacturers - General
Scan Results
Daily timeframeSanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. The company carries a $91.39B market cap, placing it firmly in the large-cap category. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Market Cap
$91.39B
Beta
0.28
P/E (TTM)
19.28
P/E (Fwd)
8.48
EPS (TTM)
$3.96
EPS (Fwd)
$9.00
ROE
6.6%
ROA
4.7%
Cash
$5.54B
Total Debt
$20.02B
Free CF
$16.67B
52W Change
-12.8%
Annual Financials
Cash vs Debt
The company holds $5.54B in cash, though total debt stands at $20.02B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $16.67B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 6.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.7% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $40.56B to $46.72B.
The relatively low beta of 0.28 suggests SAN.PA is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SAN.PA.